Aarti Pharmalabs Limited has issued a corrigendum to correct a typographical error in its dividend record date intimation, ensuring accurate regulatory compliance for its dividend declaration.

Corrigendum Details

On February 10, 2026, Aarti Pharmalabs Limited filed a corrigendum with both BSE and National Stock Exchange of India Limited to rectify an error in its dividend record date intimation dated February 09, 2026. The correction specifically addresses a typographical mistake in the mention of the financial year for which the dividend was declared.

Regulatory Filing Information

The corrigendum was submitted to both major stock exchanges where the company's shares are listed. The filing ensures compliance with Regulation 42 requirements for dividend-related communications.

Company Confirmation

Jeevan Mondkar, Company Secretary and Legal Head of Aarti Pharmalabs Limited, confirmed that except for the financial year correction, no other changes were made to the original intimation dated February 09, 2026. The company emphasized that all other details in the dividend record date intimation remain unchanged and valid.

The corrigendum demonstrates the company's commitment to maintaining accurate regulatory filings and ensuring shareholders receive correct information regarding dividend-related matters for Financial Year 2025-26.

Aarti Pharmalabs Limited has announced its financial results for Q3FY26, demonstrating mixed performance across its business segments. The pharmaceutical company, part of the diversified Aarti group with a turnover exceeding INR 130 billion, continues to navigate operational challenges while pursuing strategic expansion initiatives.

Q3FY26 Financial Performance

The company's standalone quarterly results showed operational revenue of INR 4,253 million, representing a marginal increase of 1.9% quarter-on-quarter but a decline of 9.7% year-on-year. EBITDA for the quarter stood at INR 1,030 million with a margin of 24.22%, showing significant improvement from the previous quarter's 17.76%.

Nine-Month Performance Overview

For the nine-month period ending December 2025, the company reported operational revenue of INR 12,179 million, down 1.9% compared to INR 12,417 million in the corresponding period of the previous year. EBITDA for 9M-FY26 was INR 2,720 million with a margin of 22.33%, compared to INR 2,833 million and 22.82% margin in 9M-FY25.

Business Segment Updates

The company operates across three main segments: Xanthine derivatives, API & Intermediates, and CDMO/CMO services. The Xanthine expansion project is progressing as planned with mechanical completion expected by March 2026. The expansion will increase total capacity from 5,000 MTPA to over 9,000 MTPA, with the company targeting to increase its global market share from the current 15-20% to 20-25%.

In the CDMO/CMO business, goods worth INR 49 crore were in transit as of December 31, 2025, and could not be booked in Q3FY26 revenue due to accounting standards. The company is working with 21 customers on 59 active projects, of which 40 are in the commercial stage and 19 are under different stages of development.

Operational Challenges and Outlook

The API business continues to face margin pressure despite early signs of recovery. The company plans debottlenecking of the steroid block in its API production facility to create additional capacity. However, Atali Phase 1 is experiencing operational challenges that are impacting production ramp-up, with resolution expected by the end of Q4FY26.

Earnings Call Recording Available

Following the announcement of Q3FY26 results, Aarti Pharmalabs has uploaded the audio recording of its earnings conference call on the company website under Regulation 30 compliance. The recording provides detailed insights into the company's performance and management commentary on business developments. Investors and analysts can access the recording at the company's dedicated Q3FY26 results page.

The company maintains its position as the largest Indian manufacturer of Xanthine derivatives and continues to benefit from the "China+1" shift with its non-Chinese dependent and fully backward integrated manufacturing capabilities. With USFDA approved facilities and regulatory approvals from multiple agencies including EU GMP, EDQM, KFDA, and COFEPRIS, the company is well-positioned in regulated markets.